Brivaracetam to Treat Partial Onset Seizures in Adults
Purpose of Review
Seizures are a hyperexcitable, and hypersynchronous imbalance between excitatory and inhibitory factors (E/I imbalance) in neurotransmission, and epilepsy is the recurrent manifestation of seizures within a reasonable time frame and without being attributable to a reversible cause. Brivaracetam is a derivative of the antiepileptic agent, levetiracetam, that is used as adjuvant therapy for focal onset seizures. It was approved by the FDA in 2016 and has shown promising results with minimal adverse effect reactions in clinical trials.
Recent Findings
Brivaracetam has been used in multiple clinical trials at various dosages in adults that have partial-onset seizures refractory to conventional treatment. A meta-analysis in 2016 showed that brivaracetam as adjunctive therapy was statically significant in its reduction of adults with drug-refractory seizure frequency.1 The most commonly reported adverse effects that patients who were taking brivaracetam experienced were somnolence, headache, and dizziness. Further studies are necessary to conclude long term efficacy and safety profile of brivaracetam.
Conclusion
The treatment of epilepsy with pharmacologic agents is a difficult task due to balancing the efficacy of the drug with the side effect profile that will allow for the best quality of life for the patient. There are approximately 30 antiepileptic agents for clinicians to choose from. Brivaracetam is a novel antiepileptic agent that was approved for use by the FDA in 2016 and is showing promising results as monotherapy and adjunctive therapy in individuals with drug-refractory focal seizures while minimizing adverse drug reactions.
1. Stafstrom CE, Carmant L. Seizures and epilepsy: An overview for neuroscientists. Cold Spring Harb Perspect Biol. 2015;7(5):1-19.
2. Huff JS, Murr N. Seizure, Pseudoseizures. In: StatPearls; 2018.
3. Schachter SC. Evaluation of the first seizure in adults. UpToDate. Published online 2016:1-25.
4. Al Khalili K, McWilliam M. Idiopathic Generalized Epilepsy. StatPearls Publishing
5. Korff C, Wirrell E. ILAE classification of seizures and epilepsy.
6. Huff JS, Morris DL, Kothari RU, Gibbs MA. Emergency department management of patients with seizures: A multicenter study. Acad Emerg Med. 2001;8(6):622-628. doi:10.1111/j.1553-2712.2001.tb00175.x
7. Debicki DB. Electroencephalography after a single unprovoked seizure. Seizure. 2017;49:69-73.
8. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482. doi:10.1111/e pi.12550
9. Stafstrom CE, Carmant L. Seizures and Epilepsy: An Overview for Neuroscientists. Cold Spring Harb Perspect Med. 2015;5(6):a022426. doi:10.1101/cshperspect.a022426
10. Huff JS, Fountain NB. Pathophysiology and Definitions of Seizures and Status Epilepticus. Emerg Med Clin North Am. 2011;29(1):1-13. doi:10.1016/j.emc.2010.08.001
11. Morrow AL, Suzdak PD, Karanian JW, Paul SM. Chronic ethanol administration alters y-aminobutyric acid, pentobarbital and ethanol-mediated 36Cl- uptake in cerebral cortical synaptoneurosomes. J Pharmacol Exp Ther. 1988;246(1):158-164.
12. Salinsky M, Kanter R, Dasheiff RM. Effectiveness of Multiple EEGs in Supporting the Diagnosis of Epilepsy: An Operational Curve. Epilepsia. 1987;28(4):331-334. doi:10.1111/j.1528-1157.1987.tb03652.x
13. Krumholz A, Wiebe S, Gronseth G, et al. Practice parameter: Evaluating an apparent unprovoked first seizure in adults (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2007;69(21):1996-2007. doi:10.1212/01.wnl.0000285084.93652.43
14. Lee Y. Advanced neuroimaging techniques for evaluating pediatric epilepsy. Clin Exp Pediatr. 2020;63(88).
15. Bernasconi A, Cendes F, Theodore W, et al. Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: A consensus report from the International League Against Epilepsy Neuroimaging Task Force. Epilepsia. 2019;60(6).
16. Kivekas E, Kinnunen UM, Paananen P, Kalviainen R, Haatainen K, Saranto K. Functionality of triggers for epilepsy patients assessed by text and data mining of medical and nursing records. Stud Health Technol Inform. 2016;225:128-132.
17. Fisher RS, Harding G, Erba G, Barkley GL, Wilkins A. Photic- and pattern-induced seizures: A review for the epilepsy foundation of America working group. Epilepsia. 2005;46(9):1426-1441. doi:10.1111/j.1528-1167.2005.31405.x
18. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus- Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523. doi:10.1111/epi.13121
19. Theodore WH. Effects of age and underlying brain dysfunction on the postictal state. 2011;19(2):118-120.
20. Sartori S, Nosadini M, Tessarin G, et al. First-ever convulsive seizures in children presenting to the emergency department: risk factors for seizure recurrence and diagnosis of epilepsy. Dev Med Child Neurol. 2019;61(1):82-90. doi:10.1111/dmcn.14015
21. Ramantani G, Holthausen H. Epilepsy after cerebral infection: a review of the literature and the potential for surgery. Epileptic Disord. 2017;19(2):117-136. doi:10.1684/epd.2017.0916
22. Lucke-Wold BP, Nguyen L, Turner RC, et al. Traumatic brain injury and epilepsy: Underlying mechanisms leading to seizure. Seizure. 2015;33:13-23. doi:10.1016/j.seizure.2015.10.002
23. Ferlazzo E, Gasparini S, Beghi E, et al. Epilepsy in cerebrovascular diseases: Review of experimental and clinical data with meta-analysis of risk factors. Epilepsia. 2016;57(8):1205-1214. doi:10.1111/epi.13448
24. Gloor P. Contributions of Electroencephalography and Electrocorticography to the Neurosurgical Treatment of the Epilepsies. Advances in neurology; 1975.
25. de Curtis M, Avoli M. Initiation, propagation, and termination of partial (focal) seizures. Cold Spring Harb Perspect Med. 2015;5(7):a022368. doi:10.1101/cshperspect.a022368
26. de Curtis M, Gnatkovsky V. Reevaluating the mechanisms of focal ictogenesis: The role of low-voltage fast activity. Epilepsia. Published online 2009.
27. Heinemann U, Lux HD, Gutnick MJ. Extracellular free calcium and potassium during paroxysmal activity in the cerebral cortex of the cat. Exp Brain Res. 1977;27(3-4). doi:10.1007/bf00235500
28. Trombin F, Gnatkovsky V, de Curtis M. Changes in action potential features during focal seizure discharges in the entorhinal cortex of the in vitro isolated guinea pig brain. J Neurophysiol. 2011;106(3):1411-1423. doi:10.1152/jn.00207.2011
29. Jiruska P, de Curtis M, Jefferys JGR, Schevon CA, Schiff SJ, Schindler K. Synchronization and desynchronization in epilepsy: Controversies and hypotheses. Journal of Physiology. 2013;591(4):787-797. doi:10.1113/jphysiol.2012.239590
30. Wendling F, Bartolomei F, Bellanger JJ, Bourien J, Chauvel P. Epileptic fast intracerebral EEG activity: Evidence for spatial decorrelation at seizure onset. Brain. 2003;126(6):1449-1459. doi:10.1093/brain/awg144
31. Jenssen S, Gracely EJ, Sperling MR. How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit. Epilepsia. 2006;47(9):1499-1503. doi:10.1111/j.1528-1167.2006.00622.x
32. Elwes RDC, Johnson AL, Shorvon SD, Reynolds EH. The Prognosis for Seizure Control in Newly Diagnosed Epilepsy. N Engl J Med. 1984;311(15):944-947. doi:10.1056/nejm198410113111503
33. Lowenstein D. Seizures and epilepsy. In: Fauci A, Kasper D, Longo D, eds. Harrison's Principles of Internal Medicine.; 2008:2498-2512.
34. Ben-Menachem E, Revesz D, Simon BJ, Silberstein S. Surgically implanted and non-invasive vagus nerve stimulation: A review of efficacy, safety and tolerability. Eur J Neurol. 2015;22(9):1260-1268. doi:10.1111/ene.12629
35. Krahl S. Vagus nerve stimulation for epilepsy: A review of the peripheral mechanisms. Surg Neurol Int. 2012;3(2):47. doi:10.4103/2152-7806.91610
36. Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: A randomized active-control trial. Neurology. 1998;51(1):48-55. doi:10.1212/wnl.51.1.48
37. George R, Sonnen A, Upton A, et al. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology. Published online 1995.
38. Khaleghi F, Nemec EC. Brivaracetam (Briviact): A novel adjunctive therapy for partial-onset seizures. P T. 2017;42(2):92-96.
39. Kaminski RM, Gillard M, Klitgaard H. Targeting SV2A for discovery of antiepileptic drugs. Epilepsia. 2010;51:83-83. doi:10.1111/j.1528-1167.2010.02869.x
40. Panebianco M, Bresnahan R, Hemming K, Marson AG. Pregabalin add-on for drug-resistant focal epilepsy. Cochrane Database of Systematic Reviews. Published online July 9, 2019. doi:10.1002/14651858.cd005612.pub4
41. Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol Adv Appl. 2018;10:1-22. doi:10.2147/cpaa.s114072
42. Mumoli L, Palleria C, Gasparini S, et al. Brivaracetam: Review of its pharmacology and potential use as adjunctive therapy in patients with partial-onset seizures. Drug Des Devel Ther. 2015;9:5719-5725.
43. Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. BrJ Clin Pharmacol. 2008;66(1):71-75. doi:10.1111/j.1365-2125.2008.03158.x
44. French JA, Costantini C, Brodsky A, Von Rosenstiel P. Adjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial. Neurology. 2010;75(6):519-525. doi:10.1212/wn1.0b013e3181ec7f7f
45. Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial. Epilepsia. 2013;54(1):89-97. doi:10.1111/j.1528-1167.2012.03598.x
46. Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47-56. doi:10.1111/epi.12432
47. Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as an adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57-66. doi:10.1111/epi.12433
48. Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55(1):38-46. doi:10.1111/epi.12391
49. Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890-1898. doi:10.1111/epi.13212
50. Ben-Menachem E, Mameniskiene R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016;87(3):314-323. doi:10.1212/wnl.0000000000002864
51. Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy. Neurology. 86:1344-1352.
52. Klein P, Tyrlikova I, Brazdil M, Rektor I. Brivaracetam for the treatment of epilepsy. Expert Opin Pharmacother. 2016;17(2):283-295. doi:10.1517/14656566.2016.1135129
53. Benbadis S, Klein P, Schiemann J, Diaz A, Elmoufti S, Whitesides J. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis. Epilepsy Behav. 2018;80:129-134. doi:10.1016/j.yebeh.2017.12.024
54. Moseley BD, Otoul C, Staelens L, Stockis A. Pharmacokinetic interaction of brivaracetam on other
antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials. Epilepsy Res. 2019;158:106218. doi:10.1016/j.ep lepsyres.2019.106218